TY  - JOUR
AU  - Ruiz-Sánchez, Daniel
AU  - Alaguero Calero, Miguel
AU  - Sastre-Heres, Alejandro José
AU  - Iglesias García, María Teresa
AU  - Calleja Hernandez, Miguel Angel
AU  - Martínez Martinez, Fernando
AU  - Peña-Díaz, Jaime
PY  - 2012
DO  - 10.3892/ol.2012.861
UR  - http://hdl.handle.net/10668/1406
T2  - Oncology letters
AB  - A retrospective cohort study was conducted to analyse the effectiveness of bevacizumab and irinotecan (BVZ/CPT-11) as a second-line treatment in patients with primary glioblastoma multiforme (GBM) in comparison with a control group that were not...
LA  - en
PB  - Spandidos Publications
KW  - Bevacizumab
KW  - Irinotecan
KW  - Effectiveness
KW  - Antineoplásicos
KW  - Camptotecina
KW  - Análisis de Supervivencia
KW  - Estudios de Cohortes
KW  - Anticuerpos Monoclonales
KW  - Resultado del Tratamiento
KW  - Medical Subject Headings::Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonal::Neuroectodermal Tumors::Neoplasms, Neuroepithelial::Glioma::Astrocytoma::Glioblastoma
KW  - Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Survival Analysis
KW  - Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies
KW  - Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal
KW  - Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents
KW  - Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Alkaloids::Camptothecin
KW  - Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Treatment Outcome
TI  - Effectiveness of the bevacizumab-irinotecan regimen in the treatment of recurrent glioblastoma multiforme: Comparison with other second-line treatments without this regimen.
TY  - research article
ER  -